Phase I Clinical Trials: Find Success with Medrio
Solution Sheet
Phase I clinical trials represent a major milestone in a new medical product’s journey from lab to market. The insights gathered from testing a product on humans is key to determining its viability as a treatment option and sets the tone for the whole research process. When early phase studies experience issues with site selection, recruitment, patient safety, and inefficient trial processes, it can result in costly delays to FDA submission and market arrival. Sponsors, CROs, and study managers need a flexible, unified eClinical suite to sprint their Phase 1 studies and ensure success all the way to final market approval.
The Medrio Difference for Early Phase Trials
377+
Phase I Companies
2000+
Phase I Trials
95%
Reduction in Paper
3
Weeks Average FPI
377+
Phase I Companies
2000+
Phase I Trials
95%
Reduction in Paper
3
Weeks Average FPI
A Faster, More Flexible Path to Deployment
Success in early phase trials can lay the foundation for subsequent phases. Our flexible, integrated solutions were designed to reduce inefficiencies that result in lengthy and costly delays to sponsors. Build, test, and deploy your study in days, not months, with our intuitive point-and-click interface. Watch timelines continue to shorten as you leverage our extensive library of reusable and customizable forms.
Build Studies Without IT Support
Drag-and-drop workflows remove the need for timely training or programming support so you can build eCRFs and study protocols with efficiency, speed, and control.
Customize and Configure
Early-stage studies have unique characteristics, but many follow similar designs. Access our library of customizable forms and templates or copy databases from previous studies to reuse, reconfigure, and reduce build timelines.
Streamline Site Support
eLearning videos for site staff, event- and subject-based navigation, and intuitive technology make it quick and easy to roll out study protocol to sites with minimal need for training.
The clinic team loved using the tablets for mobile data capture during that first study. They loved having to sign in only once and then being able to simply click and save a result without having to sign their name and enter a date over and over. They also loved not having to initial and supply a reason for every update or
Readily Available and Reliable Data
Rapidly progressing through early phase trials shouldn’t be at the expense of your data quality and accuracy. Our unified eSuite offers real-time, event-driven data collection to power informed decisions about your study and detect safety signals that protect patient safety.
- Clean data as it’s entered with dynamic forms and skip logic
- Leverage automatic edit checks and perform on-demand data reviews
- Keep your sites happy with reliable, real-time data and an intuitive interface
- Improve patient safety and AE detection with access to live clinical and patient-reported data
- Gain instant insight into your trial performance with robust reporting and analysis tools
- Conduct in-depth analysis as soon as study data is available – no IT support needed!
Maintain Control of Mid-Study Changes
Mid-study changes are commonplace in Phase I studies, and researchers need an efficient way to handle them without system downtime. Medrio makes it possible to review and deploy changes safely from a test environment to the live study in a matter of clicks without vendor reliance, downtime, pesky database migrations, or hidden fees.
Practical Pricing for Every Phase
Our straightforward, transparent pricing model is ideal for fast-moving Phase I studies.
- Lower your cost of ownership with pricing based on your specific site, subject, and timing needs
- Keep your studies comfortably within budget with reliable data and autonomy to build your studies the way you want them.
Medrio empowers sponsors and CROs across all phases of clinical research to accelerate their processes and reduce costs. But it’s our Phase I users who truly see the benefits of getting a strong eClinical start as a product begins its journey to market.
Subscribe To Our Newsletter
